Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please e-mail your request to news@bms.com and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts

updated Jan 2016
Chief Executive Officer:
Headquarters:
New York City
Business:
Biopharmaceuticals
Web Address:
NYSE Listing:
BMY
Net Sales:
$19.4 billion in 2016
R&D Investment:
$4.94 billion which included the discovery and development of new medicines for patients
Principal Locations:
2016 Largest-Selling Products:

OPDIVO®, $3.8 billion

ELIQUIS®, $3.3 billion

ORENCIA®, $2.3 billion

SPRYCEL®, $1.8 billion

Hepatitis C franchise, $1.6 billion

BARACLUDE®, $1.2 billion

YERVOY®, $1.1 billion

SUSTIVA® franchise, $1.1 billion

REYATAZ® franchise, $912 million

Selected Key Products:

Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.